Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
Am Heart J
; 142(4): 577-85, 2001 Oct.
Article
in En
| MEDLINE
| ID: mdl-11579345
ABSTRACT
PURPOSE:
The ACE Inhibitor After Anthracycline (AAA) study is a randomized, double-blind, controlled clinical trial comparing enalapril with placebo to determine whether treatment can slow the progression of cardiac decline in patients who screen positive for anthracycline cardiotoxicity.METHODS:
The primary outcome measure is the rate of decline, over time, in maximal cardiac index (in liters per minute per meters squared) at peak exercise; the secondary outcome measure is the rate of increase in left ventricular end systolic wall stress (in grams per centimeters squared). Patients >2 years off therapy and <4 years from diagnosis, aged 8 years and older, were eligible if they had received anthracyclines and had at least one cardiac abnormality identified at any time after anthracycline exposure.RESULTS:
A total of 135 patients were randomized to enalapril or placebo. Baseline characteristics were similar across treatment groups.CONCLUSIONS:
The AAA study will provide important information concerning the efficacy of using angiotensin-converting enzyme inhibitors to offset the effects of late anthracycline cardiotoxicity.
Search on Google
Collection:
01-internacional
Health context:
2_ODS3
Database:
MEDLINE
Main subject:
Angiotensin-Converting Enzyme Inhibitors
/
Enalapril
/
Anthracyclines
/
Heart Diseases
/
Neoplasms
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Language:
En
Journal:
Am Heart J
Year:
2001
Document type:
Article